RS20050831A - Vegfr-2 i vegfr-3 inhibirajući antranilamidpiridoni - Google Patents

Vegfr-2 i vegfr-3 inhibirajući antranilamidpiridoni

Info

Publication number
RS20050831A
RS20050831A YUP-2005/0831A YUP20050831A RS20050831A RS 20050831 A RS20050831 A RS 20050831A YU P20050831 A YUP20050831 A YU P20050831A RS 20050831 A RS20050831 A RS 20050831A
Authority
RS
Serbia
Prior art keywords
stands
cycloalkyl
halo
hydrogen
alkyl
Prior art date
Application number
YUP-2005/0831A
Other languages
English (en)
Serbian (sr)
Inventor
Andreas Huth
Karl-Heinz Thierauch
Andreas Menrad
Martin Haberey
Rolf Bohlmann
Martin Krueger
Ludwig Zorn
Stuart Ince
Stumpp Holger Hess
Original Assignee
Schering Aktiengesellschaft,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft, filed Critical Schering Aktiengesellschaft,
Publication of RS20050831A publication Critical patent/RS20050831A/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
YUP-2005/0831A 2003-06-13 2004-06-09 Vegfr-2 i vegfr-3 inhibirajući antranilamidpiridoni RS20050831A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10327719A DE10327719A1 (de) 2003-06-13 2003-06-13 VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
PCT/EP2004/006236 WO2004111005A1 (fr) 2003-06-13 2004-06-09 Anthranylamide pyridones qui inhibent vegfr-2 et vegfr-3

Publications (1)

Publication Number Publication Date
RS20050831A true RS20050831A (sr) 2008-04-04

Family

ID=33520741

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0831A RS20050831A (sr) 2003-06-13 2004-06-09 Vegfr-2 i vegfr-3 inhibirajući antranilamidpiridoni

Country Status (18)

Country Link
EP (1) EP1633713A1 (fr)
JP (1) JP2006527228A (fr)
KR (1) KR20060021887A (fr)
CN (1) CN1805936A (fr)
AU (1) AU2004247377A1 (fr)
BR (1) BRPI0411360A (fr)
CA (1) CA2526041A1 (fr)
CR (1) CR8127A (fr)
DE (1) DE10327719A1 (fr)
EA (1) EA200501885A1 (fr)
EC (1) ECSP066280A (fr)
IL (1) IL171898A0 (fr)
MX (1) MXPA05013586A (fr)
NO (1) NO20060196L (fr)
RS (1) RS20050831A (fr)
UA (1) UA81323C2 (fr)
WO (1) WO2004111005A1 (fr)
ZA (1) ZA200600291B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060071812A (ko) * 2004-12-22 2006-06-27 주식회사 엘지생명과학 신규한 3-(2-아미노-6-피리디닐)-4-히드록시페닐 아민유도체
US9376393B2 (en) * 2012-01-05 2016-06-28 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
CN106496107A (zh) * 2016-08-31 2017-03-15 浙江永宁药业股份有限公司 Vegfr‑2抑制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
WO2002090352A2 (fr) * 2001-05-08 2002-11-14 Schering Aktiengesellschaft Anthranylamides pyridine amides selectives en tant qu'inhibateurs vegfr-2 et vegfr-3
GB0126902D0 (en) * 2001-11-08 2002-01-02 Novartis Ag Organic compounds
DE10228090A1 (de) * 2002-06-19 2004-01-15 Schering Ag Ausgewählte Anthranylamidpyridinamide und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA2526041A1 (fr) 2004-12-23
DE10327719A1 (de) 2005-01-20
AU2004247377A1 (en) 2004-12-23
EA200501885A1 (ru) 2006-06-30
MXPA05013586A (es) 2006-03-09
WO2004111005A1 (fr) 2004-12-23
KR20060021887A (ko) 2006-03-08
JP2006527228A (ja) 2006-11-30
CR8127A (es) 2006-05-29
ZA200600291B (en) 2007-03-28
EP1633713A1 (fr) 2006-03-15
IL171898A0 (en) 2006-04-10
NO20060196L (no) 2006-01-12
BRPI0411360A (pt) 2006-07-25
UA81323C2 (en) 2007-12-25
ECSP066280A (es) 2006-07-28
CN1805936A (zh) 2006-07-19

Similar Documents

Publication Publication Date Title
JP4777648B2 (ja) Vegfr−2及びvegfr−3阻害性アントラニルアミドピリジン
CN100374435C (zh) 具有血管生成抑制活性的取代的哒嗪
RU2415850C2 (ru) Новые антраниламидопиридинмочевины в качестве ингибиторов киназы рецептора vegf
HK1217482A1 (en) Enzyme modulators and therapies
JP2007513172A (ja) 複素環式プロテインキナーゼインヒビターおよびその使用
JP2010519174A (ja) c−Metの複素環阻害薬およびその使用方法
JP2007506763A (ja) プロテインキナーゼのインヒビターとして有用なイミダゾール組成物
JP4343681B2 (ja) シアノアントラニルアミド誘導体およびそれらの薬剤としての使用
US20070135489A1 (en) Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridones
MX2007005340A (es) Novedosas piridinurea nicotinamidas como inhibidores de quinasas de receptores del factor de crecimiento del endotelio vascular (vegf).
RS20050831A (sr) Vegfr-2 i vegfr-3 inhibirajući antranilamidpiridoni
JP2004532241A (ja) 血管形成阻害活性を有するフタラジン誘導体
HK1109403B (en) Anthranilamide pyridinureas as vegf receptor kinase inhibitors
HK1089171A (en) Anthranylamide pyridones that inhibit vegfr-2 and vegfr-3
BR102017016829A2 (pt) Derivados de oxadiazolopiridina para uso como inibidores de grelina o-acil transferase (goat)